Star Therapeutics raises $200 million to advance pipeline after spinout successes
Star Therapeutics has secured $200 million in private financing to advance its preclinical programs into clinical trials and expand its pipeline. The funding follows the company's successful track record of spinning out companies including Vega and Electra, with Incyte acquiring one of its spinouts in July 2026.
